# Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment

> **NCT06031259** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Takeda** · enrollment: 6 (actual)

## Conditions studied

- Hunter Syndrome

## Interventions

- **DRUG:** Idursulfase-IT
- **DRUG:** Elaprase

## Key facts

- **NCT ID:** NCT06031259
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-05
- **Primary completion:** 2029-01-01
- **Final completion:** 2029-01-01
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06031259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06031259, "Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06031259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*